Curcumin-artemisinin coamorphous solid: Xenograft model preclinical study
| Title | Curcumin-artemisinin coamorphous solid: Xenograft model preclinical study |
| Publication Type | Journal Article |
| Year of Publication | 2018 |
| Authors | Mannava, MKChaitan, Suresh, K, Bommaka, MKumar, Konga, DBhavani, Nangia, A |
| Journal | Pharmaceutics |
| Volume | 10 |
| Issue | 1 |
| Pagination | Article Number: 7 |
| Date Published | MAR |
| Abstract | Curcumin is a natural compound present in Indian spice turmeric. It has diverse pharmacological action but low oral solubility and bioavailability continue to limit its use as a drug. With the aim of improving the bioavailability of Curcumin (CUR), we evaluated Curcumin-Pyrogallol (CUR-PYR) cocrystal and Curcumin-Artemisinin (CUR-ART) coamorphous solid. Both of these solid forms exhibited superior dissolution and pharmacokinetic behavior compared to pure CUR, which is practically insoluble in water. CUR-ART coamorphous solid showed two fold higher bioavailability than CUR-PYR cocrystal (at 200 mg/kg oral dose). Moreover, in simulated gastric and intestinal fluids (SGF and SIF), CUR-ART is stable up to 3 and 12 h, respectively. In addition, CUR-PYR and CUR-ART showed no adverse effects in toxicology studies (10 times higher dose at 2000 mg/kg). CUR-ART showed higher therapeutic effect and inhibited approximately 62% of tumor growth at 100 mg/kg oral dosage of CUR in xenograft models, which is equal to the positive control drug, doxorubicin (2 mg/kg) by i.v. administration. |
| DOI | 10.3390/pharmaceutics10010007 |
| Type of Journal (Indian or Foreign) | Foreign |
| Impact Factor (IF) | 3.649 |
Divison category:
Physical and Materials Chemistry